ClinicalTrials.gg
CompletedNCT02164864Updated Jul 31, 2018Results posted

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

A Phase 3 interventional study of Dabigatran Etexilate 110mg and Warfarin 3mg in Atrial Fibrillation and Percutaneous Coronary Intervention, sponsored by Boehringer Ingelheim. Completed at 421 sites in 41 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-31.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,725
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing dabigatran in Atrial Fibrillation — none open to participants now, 1 under way, none of them phase 3. Dabigatran · Atrial Fibrillation.

Enrollment
2nd of 35
2,725 · median 174
Started
2014
with 3 others
Phase 3
6 of 35
none open now
Registered
17th of 35
by date
Lead sponsor
7 of 35
Boehringer Ingelheim

Among the 35 studies testing dabigatran in Atrial Fibrillation, this one is the 2nd largest by enrollment, is one of 4 that started in 2014, is one of 6 in phase 3, and was the 17th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

None of the 35 studies testing dabigatran in Atrial Fibrillation is open now. The open studies under Atrial Fibrillation, anywhere →

About dabigatran

Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies testing dabigatran in Atrial Fibrillation as a file.
02

Study summary

The main objective of this study is to compare a Dual Antithrombotic Therapy (DAT) regimen of 110mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (110mg dabigatran etexilate (DE) DAT) and 150mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (150mg DE-DAT) with a Triple Antithrombotic Therapy (TAT) combination of warfarin plus clopidogrel or ticagrelor plus Aspirin (ASA) \<= 100mg once daily (warfarin-TAT) in patients with Atrial Fibrillation that undergo a PCI with stenting (elective or due to an Acute Coronary Syndrome).

The study aims to show non-inferiority of each dose of DE-DAT when compared to Warfarin-TAT in terms of safety. Safety will be determined by comparing the rates of bleeding events, assessed using the modified International Society of Thrombosis and Haemostasis classification of Major Bleeding and Clinically Relevant Non Major Bleeding Events.

03

Conditions studied

  • Atrial Fibrillation
  • Percutaneous Coronary Intervention

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged >=18 years
  • Patients with Non Valvular Atrial Fibrillation
  • Patient presenting with:

An Acute Coronary Syndrome (ACS) (ST elevation myocardial infarction (STEMI), NonSTEMI [NSTEMI] or unstable angina [UA]) that was successfully treated by PCI and stenting (either Bare Metal Stent (BMS) or Drug Eluting Stent) Or Stable Coronary Artery Disease with at least one lesion eligible for PCI that was successfully treated by elective PCI and stenting (either BMS or DES)

  • The patient must be able to give in accordance with International Conference on Harmonisation Good Clinical Practice guidelines and local legislation and/or regulations.

Exclusion criteria

Exclusion criteria:

  • Patients with a mechanical or biological heart valve prosthesis
  • Cardiogenic shock during current hospitalisation
  • Stroke within 1 month prior to screening visit
  • Patients who have had major surgery within the month prior to screening
  • Gastrointestinal haemorrhage within one month prior to screening, unless, in the opinion of the Investigator, the cause has been permanently eliminated
  • Major bleeding episode including life-threatening bleeding episode in one month prior to screening visit
  • Anaemia ( \<10g/dL) or thrombocytopenia including heparin-induced thrombocytopenia ( count \<100 x 109/L) at screening
  • Severe renal impairment (estimated (CrCl) calculated by Cockcroft-Gault equation) \<30mL/min at screening
  • Active liver disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,725 participants (actual)

Study arms

  • Experimental
    Dabigatran Etexilate 110mg

    Patient to receive Dabigatran Etexilate 110mg twice a day (BID)

    Drug: Dabigatran Etexilate 110mg · Drug: Clopidogrel or Ticagrelor

  • Experimental
    Dabigatran Etexilate 150mg

    Patient to receive Dabigatran Etexilate 150mg twice a day (BID)

    Drug: Dabigatran Etexilate 150mg · Drug: Clopidogrel or Ticagrelor

  • Active comparator
    Warfarin

    Warfarin doses to maintain INR

    Drug: Warfarin 3mg · Drug: Aspirin · Drug: Clopidogrel or Ticagrelor · Drug: Warfarin 5mg · Drug: Warfarin 1mg

Interventions

06

What researchers measure

Primary outcomes

  1. Time to First Adjudicated ISTH MBE or CRNMBE

    Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported. Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial. Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status. Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'.

    Time frame: up to 30 months

Secondary outcomes

  1. Time to Adjudicated Undetermined Cause of Death

    Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported. This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was "patient died") or when there was insufficient supporting information or detail to assign the cause of death.

    Time frame: up to 30 months

  2. Time to Adjudicated Non-CV

    Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported. Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV

    Time frame: up to 30 months

  3. Time to Adjudicated CV

    Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported. CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes.

    Time frame: up to 30 months

  4. Time to Adjudicated All Cause Death

    Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death.

    Time frame: up to 30 months

  5. Time to First Adjudicated MI

    Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported

    Time frame: up to 30 months

  6. Time to First Adjudicated Stroke

    Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction

    Time frame: up to 30 months

  7. Time to First Adjudicated SE

    Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported. SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy.

    Time frame: up to 30 months

  8. Time to First Adjudicated ST

    Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported.

    Time frame: up to 30 months

  9. Time to Composite Endpoint of Death + MI + Stroke

    Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported.

    Time frame: up to 30 months

  10. Time to Composite Endpoint of Death or First Thrombotic Event

    Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE).

    Time frame: up to 30 months

  11. Time to First Adjudicated Unplanned Revascularisation by PCI/CABG

    Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported.

    Time frame: up to 30 months

  12. Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG

    Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported.

    Time frame: up to 30 months

07

Results

Posted Jul 31, 2018

Participant flow

Patients aged ≥80 years in the United States of America (USA) were assigned to 110 milligram (mg) Dual antithrombotic therapy with dabigatran etexilate (DE-DAT), 150 mg DE-DAT, or warfarin. All other patients including aged ≥80 years (for Japan ≥70 years) outside of the USA were assigned to 110 mg DE-DAT or warfarin

Participant flow — Overall Study
MilestoneDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarin
Started981763981
Completed886703849
Not completed9560132
Withdrew: Trial disease worsening751
Withdrew: Other pre-existing disease worsening649
Withdrew: Other adverse event (ae)523249
Withdrew: Protocol violation241
Withdrew: Lost to follow-up432
Withdrew: Consent withdrawn, not due to ae21856
Withdrew: Other than stated3414

Outcome measures

PrimaryTime to First Adjudicated ISTH MBE or CRNMBE

Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported. Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial. Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status. Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'.

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to First Adjudicated ISTH MBE or CRNMBE
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USA)
Time to First Adjudicated ISTH MBE or CRNMBE151154264196
Statistical analysis
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = <0.0001 (P values for noninferiority were calculated at a one-sided alpha level of 0.025) · Hazard ratio (hr): 0.52 · 95% CI 0.42 to 0.63Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = <.0001 (P-values for non-inferiority were calculated at a one-sided alpha level of 0.025) · Hazard ratio (hr): 0.72 · 95% CI 0.58 to 0.88Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = <0.001 (Wald 2-sided p-value from (stratified) Cox proportional hazards model) · Hazard ratio (hr): 0.52 · 95% CI 0.42 to 0.63Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = 0.0020 (unstratified Cox proportional hazards model was used and elderly patients outside the USA were excluded) · Hazard ratio (hr): 0.72 · 95% CI 0.58 to 0.88Wald 2-sided p-value from (unstratified) Cox proportional hazards model
SecondaryTime to Adjudicated Undetermined Cause of Death

Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported. This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was "patient died") or when there was insufficient supporting information or detail to assign the cause of death.

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to Adjudicated Undetermined Cause of Death
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USA)
Time to Adjudicated Undetermined Cause of Death4543
Statistical analysis
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = 0.9862 (Wald 2-sided p-value from (stratified) Cox proportional hazards model) · Hazard ratio (hr): 0.99 · 95% CI 0.25 to 3.95Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = 0.5277 · Hazard ratio (hr): 1.59 · 95% CI 0.38 to 6.64Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
SecondaryTime to Adjudicated Non-CV

Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported. Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to Adjudicated Non-CV
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USA)
Time to Adjudicated Non-CV144138
Statistical analysis
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = 0.8853 (Wald 2-sided p-value from (stratified) Cox proportional hazards model) · Hazard ratio (hr): 1.06 · 95% CI 0.50 to 2.25Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = 0.2380 (Wald 2-sided p-value from (unstratified) Cox proportional hazards model) · Hazard ratio (hr): 0.49 · 95% CI 0.15 to 1.61Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
SecondaryTime to Adjudicated CV

Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported. CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes.

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to Adjudicated CV
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USA)
Time to Adjudicated CV37213124
Statistical analysis
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = 0.5252 (Wald 2-sided p-value from (stratified) Cox proportional hazards model) · Hazard ratio (hr): 1.17 · 95% CI 0.72 to 1.88Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = 0.5670 (Wald 2-sided p-value from (unstratified) Cox proportional hazards model) · Hazard ratio (hr): 0.84 · 95% CI 0.47 to 1.51Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
SecondaryTime to Adjudicated All Cause Death

Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death.

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to Adjudicated All Cause Death
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USA)
Time to Adjudicated All Cause Death55304835
Statistical analysis
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = 0.5579 (Wald 2-sided p-value from (stratified) Cox proportional hazards model) · Hazard ratio (hr): 1.12 · 95% CI 0.76 to 1.65Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = 0.4414 (Wald 2-sided p-value from (unstratified) Cox proportional hazards model) · Hazard ratio (hr): 0.83 · 95% CI 0.51 to 1.34Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
SecondaryTime to First Adjudicated MI

Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to First Adjudicated MI
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USA)
Time to First Adjudicated MI44262922
Statistical analysis
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = 0.0861 · Hazard ratio (hr): 1.51 · 95% CI 0.94 to 2.41Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = 0.6144 (Wald 2-sided p-value from (unstratified) Cox proportional hazards model) · Hazard ratio (hr): 1.16 · 95% CI 0.66 to 2.04Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
SecondaryTime to First Adjudicated Stroke

Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported. Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to First Adjudicated Stroke
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USA)
Time to First Adjudicated Stroke179138
Statistical analysis
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = 0.4803 (Wald 2-sided p-value from (stratified) Cox proportional hazards model) · Hazard ratio (hr): 1.30 · 95% CI 0.63 to 2.67Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = 0.8537 (Wald 2-sided p-value from (unstratified) Cox proportional hazards model) · Hazard ratio (hr): 1.09 · 95% CI 0.42 to 2.83Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
SecondaryTime to First Adjudicated SE

Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported. SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy.

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to First Adjudicated SE
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USA)
Time to First Adjudicated SE3133
Statistical analysis
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = 0.9388 (Wald 2-sided p-value from (stratified) Cox proportional hazards model) · Hazard ratio (hr): 0.94 · 95% CI 0.19 to 4.66Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = 0.3030 (Wald 2-sided p-value from (unstratified) Cox proportional hazards model) · Hazard ratio (hr): 0.30 · 95% CI 0.03 to 2.93Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
SecondaryTime to First Adjudicated ST

Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported.

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to First Adjudicated ST
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USA)
Time to First Adjudicated ST15787
Statistical analysis
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = 0.1546 (Wald 2-sided p-value from (stratified) Cox proportional hazards model) · Hazard ratio (hr): 1.86 · 95% CI 0.79 to 4.40Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = 0.9789 (Wald 2-sided p-value from (unstratified) Cox proportional hazards model) · Hazard ratio (hr): 0.99 · 95% CI 0.35 to 2.81Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
SecondaryTime to Composite Endpoint of Death + MI + Stroke

Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported.

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to Composite Endpoint of Death + MI + Stroke
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USA)
Time to Composite Endpoint of Death + MI + Stroke107608057
Statistical analysis
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = 0.0484 (Wald 2-sided p-value from (stratified) Cox proportional hazards model) · Hazard ratio (hr): 1.34 · 95% CI 1.00 to 1.79Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = 0.8903 (Wald 2-sided p-value from (unstratified) Cox proportional hazards model) · Hazard ratio (hr): 1.03 · 95% CI 0.71 to 1.47Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
SecondaryTime to Composite Endpoint of Death or First Thrombotic Event

Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE).

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to Composite Endpoint of Death or First Thrombotic Event
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USAAll Dabigatran Etexilate
Time to Composite Endpoint of Death or First Thrombotic Event108608360168
Statistical analysis
  • Warfarin vs All Dabigatran Etexilate · Regression, Cox · p = 0.1128 (P values for noninferiority were calculated at a one-sided alpha level of 0.025) · Hazard ratio (hr): 1.17 · 95% CI 0.90 to 1.53The upper bound of the Wald confidence interval (CI) of the HR of All Dabigatran Etexilate (110mg and 150 mg) vs Warfarin (one-sided 97.5%) was compared with this noninferiority margin for the testing of non-inferiority
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = 0.0720 (Wald 2-sided p-value from (stratified) Cox proportional hazards model) · Hazard ratio (hr): 1.30 · 95% CI 0.98 to 1.73Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA · Regression, Cox · p = 0.8750 (Wald 2-sided p-value from (unstratified) Cox proportional hazards model) · Hazard ratio (hr): 0.97 · 95% CI 0.68 to 1.39Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
SecondaryTime to First Adjudicated Unplanned Revascularisation by PCI/CABG

Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported.

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to First Adjudicated Unplanned Revascularisation by PCI/CABG
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USA)
Time to First Adjudicated Unplanned Revascularisation by PCI/CABG76516952
Statistical analysis
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = 0.6080 (Wald 2-sided p-value from (stratified) Cox proportional hazards model) · Hazard ratio (hr): 1.09 · 95% CI 0.79 to 1.51Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = 0.8348 (Wald 2-sided p-value from (unstratified) Cox proportional hazards model) · Hazard ratio (hr): 0.96 · 95% CI 0.65 to 1.41Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
SecondaryTime to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG

Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported.

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG
ParticipantsDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinWarfarin (Excluding Elder Patients Outside USA)All Dabigatran Etexilate
Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG1499013198239
Statistical analysis
  • Warfarin vs All Dabigatran Etexilate · Regression, Cox · p = 0.0047 (P values for noninferiority were calculated at a one-sided alpha level of 0.025) · Hazard ratio (hr): 1.04 · 95% CI 0.84 to 1.29The upper bound of the Wald confidence interval (CI) of the HR of All Dabigatran Etexilate (110mg and 150 mg) vs Warfarin (one-sided 97.5%) was compared with this noninferiority margin for the testing of non-inferiority
  • Dabigatran Etexilate 110mg vs Warfarin · Regression, Cox · p = 0.3002 (Wald 2-sided p-value from (stratified) Cox proportional hazards model) · Hazard ratio (hr): 1.13 · 95% CI 0.90 to 1.43Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model
  • Dabigatran Etexilate 150mg vs Warfarin (Excluding Elder Patients Outside USA) · Regression, Cox · p = 0.4432 (Wald 2-sided p-value from (unstratified) Cox proportional hazards model) · Hazard ratio (hr): 0.89 · 95% CI 0.67 to 1.19Hazard Ratio (HR) and Wald confidence intervals are derived from a Cox proportional-hazard model

Adverse events

Collected over From the first intake of randomised trial drug until 6 days after the last intake of the randomised trial drug, ie., up to 31 Months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran Etexilate 110mg38/972 (3.9%)415/972 (42.7%)128/972 (13.2%)
Dabigatran Etexilate 150mg24/758 (3.2%)300/758 (39.6%)126/758 (16.6%)
Warfarin41/948 (4.3%)396/948 (41.8%)229/948 (24.2%)
Most frequent serious events
Showing 10 of 542
Most frequent serious events
EventDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarin
Cardiac failureCardiac disorders48/97230/75846/948
Atrial fibrillationCardiac disorders44/97236/75834/948
Angina unstableCardiac disorders26/97215/75813/948
Vascular stent thrombosisGeneral disorders25/97210/75817/948
Angina pectorisCardiac disorders20/97218/75818/948
Acute myocardial infarctionCardiac disorders20/97214/75815/948
PneumoniaInfections and infestations20/97215/75819/948
Cardiac failure congestiveCardiac disorders14/97213/75819/948
Chest painGeneral disorders14/97215/75815/948
Atrial flutterCardiac disorders18/9728/7586/948
Most frequent other events
Most frequent other events
EventDabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarin
EpistaxisRespiratory, thoracic and mediastinal disorders52/97259/758146/948
DyspnoeaRespiratory, thoracic and mediastinal disorders62/97260/75861/948
HaematomaVascular disorders27/97224/75860/948

Baseline characteristics

The anaysis set used was Full analysis set (FAS)

Age, Continuous
Age, Continuous(Years)Dabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinTotal
Mean71.5 ± 8.8768.6 ± 7.6571.7 ± 8.9070.8 ± 8.66
Age, Customized
Age, Customized(Participants)Dabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinTotal
<80: EU/ROW7256997182142
<80: USA545361168
≥80: EU/ROW1893192384
≥80: USA1381031
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinTotal
Female253171231655
Male7285927502070
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinTotal
Hispanic or Latino704659175
Not Hispanic or Latino9037009042507
Unknown or Not Reported8171843
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dabigatran Etexilate 110mgDabigatran Etexilate 150mgWarfarinTotal
Asian11679125320
Black57315
White8516588352344
Other58720
Missing4111126
08

Study locations

421 sites
  • Cardiology P.C.
    Birmingham, Alabama 35211, United States
  • Verde Valley Medical Center
    Cottonwood, Arizona 86326, United States
  • Cardiovascular Associates of Mesa
    Mesa, Arizona 85206, United States
  • HonorHealth Research Institute
    Scottsdale, Arizona 85258, United States
  • Arkansas Cardiology, PA
    Little Rock, Arkansas 72205, United States
  • Mission Cardiovascular Research Institute
    Fremont, California 94538, United States
  • Aurora Denver Cardiology Associates, PC
    Aurora, Colorado 80012, United States
  • University of Florida College of Medicine
    Jacksonville, Florida 32209, United States
  • Watson Clinic, LLP
    Lakeland, Florida 33805, United States
  • Community Clinical Research Center
    Anderson, Indiana 46011, United States
  • Midwest Cardiovascular Research and Education Foundation
    Elkhart, Indiana 46514, United States
  • Ball Memorial Hospital
    Muncie, Indiana 47303, United States
  • Richmond Cardiology Associates Research, LLC
    Richmond, Indiana 47374, United States
  • Cardiovascular Institute of the South
    Houma, Louisiana 70360, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Cape Cod Research Institute
    Hyannis, Massachusetts 02601, United States
  • Mid Michigan Medical Center
    Midland, Michigan 48670, United States
  • Covenant Medical Center, Inc.
    Saginaw, Michigan 48602, United States
  • Saint Mary's Medical Center dba Essentia Health Saint Mary's Medical Center
    Duluth, Minnesota 55805, United States
  • CentraCare Heart and Vascular Center
    Saint Cloud, Minnesota 56303, United States
  • Kansas City Veterans Administration Medical Center
    Kansas City, Missouri 64128, United States
  • Saint Anthony's Medical Center
    Saint Louis, Missouri 63128, United States
  • St. Michaels Medical Center
    Newark, New Jersey 07102, United States
  • Lourdes Cardiology Services
    Voorhees, New Jersey 08043, United States
  • VA Western New York Healthcare System
    Buffalo, New York 14215, United States
  • Novant Health Heart and Vascular Institute
    Charlotte, North Carolina 28204, United States
  • Altru Health System
    Grand Forks, North Dakota 58201, United States
  • Cardiovascular Research Center
    Toledo, Ohio 43608, United States
  • Chambersburg Hospital
    Chambersburg, Pennsylvania 17201, United States
  • Pinnacle Health Harrisburg Hospital
    Harrisburg, Pennsylvania 17101, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Chattanooga Heart Institute
    Chattanooga, Tennessee 37404, United States
  • The Jackson Clinic, PA
    Jackson, Tennessee 38301, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-8802, United States
  • Dallas VA Medical Center
    Dallas, Texas 75216, United States
  • North Dallas Research Associates
    McKinney, Texas 75069, United States
  • Scott and White Healthcare
    Round Rock, Texas 78665, United States
  • South Texas Cardiovascular Consultants
    San Antonio, Texas 78201, United States
  • Wichita Falls Heart Clinic
    Wichita Falls, Texas 76301, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84132, United States
  • Sentara Norfolk General Hospital
    Norfolk, Virginia 23507, United States
  • Bayview Physicians Services PC dba Cardiovascular Associates
    Virginia Beach, Virginia 23454, United States
  • Holy Family Memorial, Inc
    Manitowoc, Wisconsin 54220, United States
  • Fundación Favaloro
    Caba, C1093AAS, Argentina
  • Hospital Italiano de Buenos Aires
    Caba, C1199ABB, Argentina
  • Instituto Cardiovascular de Buenos Aires
    Caba, C1428DCO, Argentina
  • Consultorios Asociados de Endocrinología e Invest Clínica
    Capital Federal, C1425AGC, Argentina
  • Instituto de Cardiología de Corrientes
    Corrientes, W3400AMZ, Argentina
  • Sanatorio Allende
    Córdoba, X5000BFB, Argentina
  • Instituto CER
    Quilmes, B1878DVB, Argentina
  • Inst.Cardiovascular San Luis
    San Luis, D5702JRS, Argentina
  • Investigaciones Clinicas Tucumán
    San Miguel de Tucumán, T4000ICL, Argentina
  • Pendlebury Research
    Adamstown, New South Wales 2289, Australia
  • Gosford Hospital
    Gosford, New South Wales 2250, Australia
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Wollongong Hospital
    Wollongong, New South Wales 2500, Australia
  • The Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Heartcare Victoria
    Bundoora, Victoria 3083, Australia
  • The Geelong Hospital
    Geelong, Victoria 3220, Australia
  • Order Hospital Elisabethinen Linz
    Linz, 4020, Austria
  • LKH Salzburg, Univ. Clinic
    Salzburg, 5020, Austria
  • Wilhelminenspital
    Wien, 1160, Austria
  • Aalst - HOSP Onze-Lieve-Vrouw
    Aalst, 9300, Belgium
  • Bonheiden - HOSP Imelda
    Bonheiden, 2820, Belgium
  • Brussels-UNIV Brugmann -Horta
    Brussel, 1020, Belgium
  • Brussels - UNIV UZ Brussel
    Brussel, 1090, Belgium
  • AZ Sint-Lucas - Campus Sint Lucas
    Gent, 9000, Belgium
  • Charleroi - HOSP St-Joseph
    Gilly, 6060, Belgium
  • Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Middelheim
    Middelheim, 2020, Belgium
  • Sint-Niklaas - HOSP AZ Nikolaas (Campus St-Niklaas)
    Sint-Niklaas, 9100, Belgium
  • Tienen - PRAC De Wolf, Axel
    Tienen, 3300, Belgium
  • Brussels - HOSP Europe (Ste-Elisabeth)
    Ukkel, 1180, Belgium
  • Hospital Santa Isabel
    Blumenau, 89010-500, Brazil
  • Irmandade da Santa Casa de Misericordia de Curitiba
    Campina Grande do Sul, 83430-000, Brazil
  • Instituto de Cardiologia Rio Grande do Sul
    Porto Alegre, 90620-001, Brazil
  • Hospital de Base - Fac Med de Sao Jose do Rio Preto
    Sao Jose do Rio Preto, 15090-000, Brazil
  • Instituto Dante Pazzanese de Cardiologia
    Sao Paulo, 04012-909, Brazil
  • Hospital Sao Paulo - UNIFESP
    Sao Paulo, 04024-002, Brazil
  • INCOR e Hospital das Clínicas da Universidade de São Paulo
    Sao Paulo, 05403-000, Brazil
  • Eurolatino pesquisas Médicas Ltda
    Uberlandia, 38411-186, Brazil
  • MHAT "Deva Maria", Dept. of Cardiology, Burgas
    Burgas, 8127, Bulgaria
  • SHAT in Cardiology EAD, Pleven
    Pleven, 5800, Bulgaria
  • MHAT"Sv.Georgi",Cardi.Clin.
    Plovdiv, 4001, Bulgaria
  • MHAT "Sv. Vrach" EOOD, Cardiology Dept., Sandanski
    Sandanski, 2800, Bulgaria
  • City Clin.Univ.MPHAT EOOD,Clin.of Cardiology, Sofia
    Sofia, 1407, Bulgaria
  • Specialized Hosp.f.Active Treatment, Cardiology Dept, Yambol
    Yambol, 8600, Bulgaria
  • Calgary Heart Centre
    Calgary, Alberta T2N 4Z6, Canada
  • St. Boniface General Hospital
    Winnipeg, Manitoba R2H 2A6, Canada
  • Hamilton General Hospital
    Hamilton, Ontario L8L 2X2, Canada
  • Kawartha Cardiology Clinical Trials
    Peterborough, Ontario K9J 0B2, Canada
  • Dr. R. Labonte Prof. Med. Corp
    Sudbury, Ontario P3E 3B8, Canada
  • Thunder Bay Regional Health Science Centre
    Thunder Bay, Ontario P7B 6V4, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Royal Victoria Hospital
    Montreal, Quebec H3A 1A1, Canada
  • CHUS Fleurimont
    Sherbrooke, Quebec J1H 5N4, Canada
  • IUCPQ (Laval University)
    Ste-Foy, Quebec GLV 4G5, Canada

Showing the first 100 of 421 sites across 41 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Godoy LC, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. Drugs. 2020 Jul;80(10):995-1005. doi: 10.1007/s40265-020-01323-x. PubMed 32562206 ↗
  • De Caterina R, Procopio A, Lopez Sendon JL, Raev D, Mehta SR, Opolski G, Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Kleine E, Ten Berg JM, Bhatt DL, Miede C, Nordaby M, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. Am J Med. 2020 Nov;133(11):1302-1312. doi: 10.1016/j.amjmed.2020.03.045. Epub 2020 May 7. PubMed 32389658 ↗
  • Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. Circ Cardiovasc Interv. 2020 Apr;13(4):e008349. doi: 10.1161/CIRCINTERVENTIONS.119.008349. Epub 2020 Apr 7. PubMed 32252548 ↗
  • Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Kiss RG, Ongen Z, Navarro Estrada JL, Oude Ophuis T, Lip GYH, Nordaby M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP; RE-DUAL PCI Steering Committee and Investigators. Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. JACC Cardiovasc Interv. 2019 Aug 26;12(16):1553-1561. doi: 10.1016/j.jcin.2019.05.050. PubMed 31439336 ↗
  • Chi G, Kerneis M, Kalayci A, Liu Y, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM. Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. Am Heart J. 2018 Sep;203:17-24. doi: 10.1016/j.ahj.2018.06.003. Epub 2018 Jun 13. PubMed 30015064 ↗
  • Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27. PubMed 28844193 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Jun 2017, 34 months.

Results were first posted in Jul 2018, 1 year 1 month after primary completion.

Of 83 phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2014
First posted
Jun 17, 2014
StartActual
Jul 22, 2014
Primary completionActual
Jun 5, 2017
CompletionActual
Jun 5, 2017
Results first posted
Jul 31, 2018
Last update
Jul 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02164864
Responsible party
Sponsor
First posted
Jun 17, 2014
Start date
Jul 22, 2014
Primary completion
Jun 5, 2017
Completion
Jun 5, 2017
Results posted
Jul 31, 2018
Last update
Jul 31, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion